deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02896907

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

A Pilot Study of Intravenous Ascorbic Acid and Folfirinox in the Treatment of Advanced Pancreatic Cancer

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Conditions Pancreatic Adenocarcinoma Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unresectable Pancreatic Carcinoma
Interventions Ascorbic Acid Fluorouracil Irinotecan Hydrochloride Leucovorin Calcium Oxaliplatin
Updated 14 times since 2017 Last updated: Apr 28, 2025 Started: Oct 18, 2016 Primary completion: Mar 22, 2018 Completion: Mar 31, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02896907, this EARLY_PHASE1 trial focuses on Pancreatic Adenocarcinoma and Recurrent Pancreatic Carcinoma and remains completed. Sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, it has been updated 14 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Apr 2018 · 10 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Feb 2026 · 9 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed EARLY_PHASE1

  2. May 2025 — Feb 2026 [monthly]

    Completed EARLY_PHASE1

  3. Sep 2024 — May 2025 [monthly]

    Completed EARLY_PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  5. Jan 2023 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

▶ Show 9 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed EARLY_PHASE1

  2. Jan 2021 — Dec 2022 [monthly]

    Completed EARLY_PHASE1

  3. Feb 2020 — Jan 2021 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

  4. May 2019 — Feb 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting EARLY_PHASE1

  6. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  7. Jun 2017 — Apr 2018 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting · Phase: NA → EARLY_PHASE1

  8. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting NA

  9. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations